Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP
Status:
NOT_YET_RECRUITING
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
Randomized, open-label, multicentre study to assess the efficacy and safety of the combination of low-dose rituximab and Iguratimod in patients with steroid-resistant/relapsed ITP.
Phase:
PHASE2
Details
Lead Sponsor:
Peking University People's Hospital
Collaborators:
Beijing Friendship Hospital Beijing Hospital Beijing Tongren Hospital Navy General Hospital, Beijing